Search results (1345)
« Back to PublicationsMOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
Verstovsek S. et al, (2021), Future oncology (London, England)
The mTOR regulated RNA-binding protein LARP1 requires PABPC1 for guided mRNA interaction.
Smith EM. et al, (2021), Nucleic Acids Res, 49, 458 - 478
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.
Baird RD. et al, (2021), J Clin Oncol, 39, 145 - 154
The Oxford Classic links epithelial-mesenchymal transition to immunosuppression in poor prognosis ovarian cancers
AHMED A. et al, (2021), Clinical Cancer Research
Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma.
Rampotas A. et al, (2021), Ther Adv Hematol, 12
Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies.
Mughal TI. et al, (2020), Hematol Oncol, 38, 654 - 664
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy.
Straus D. et al, (2020), Leuk Lymphoma, 61, 2931 - 2938
TARGET-Seq: A Protocol for High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing.
Rodriguez-Meira A. et al, (2020), STAR protocols, 1, 100125 - 100125
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.
Gerds AT. et al, (2020), Blood Adv, 4, 5825 - 5835
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.
Noy A. et al, (2020), Blood Adv, 4, 5773 - 5784
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.
Middleton MR. et al, (2020), Clin Cancer Res, 26, 5869 - 5878
Subcellular mRNA Localization Regulates Ribosome Biogenesis in Migrating Cells.
Dermit M. et al, (2020), Dev Cell, 55, 298 - 313.e10
Molecular Characterisation of Participants in the Phazar Trial Reveals Prognostic Impact of Mutations in Advanced-Phase-MPN
Brierley CK. et al, (2020), BLOOD, 136
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Ascierto PA. et al, (2020), Lancet Oncol, 21, 1465 - 1477
Efficacy and infection morbidity of front-line immuno-chemotherapy in follicular lymphoma.
Djebbari F. et al, (2020), Eur J Haematol, 105, 667 - 671